Search Results
Search for other papers by H Yamashita in
Google Scholar
PubMed
Search for other papers by M Nishio in
Google Scholar
PubMed
Search for other papers by Y Ando in
Google Scholar
PubMed
Search for other papers by Z Zhang in
Google Scholar
PubMed
Search for other papers by M Hamaguchi in
Google Scholar
PubMed
Search for other papers by K Mita in
Google Scholar
PubMed
Search for other papers by S Kobayashi in
Google Scholar
PubMed
Search for other papers by Y Fujii in
Google Scholar
PubMed
Search for other papers by H Iwase in
Google Scholar
PubMed
strong prognostic molecular marker in ER-positive breast cancer. Positive Stat5 expression predicts response to endocrine therapy and increases post-relapse survival in metastatic breast cancer patients who received first-line treatment with endocrine
Search for other papers by A Agrawal in
Google Scholar
PubMed
Search for other papers by E Gutteridge in
Google Scholar
PubMed
Search for other papers by J M W Gee in
Google Scholar
PubMed
Search for other papers by R I Nicholson in
Google Scholar
PubMed
Search for other papers by J F R Robertson in
Google Scholar
PubMed
-oestrogen-resistant breast cancer, and this agent will therefore comprise the principal focus of this overview. EGFR TKI, gefitinib, in pre-clinical breast cancer studies Gefitinib is a low molecular weight inhibitor with highly selective and reversible
Search for other papers by Sílvia F Sousa in
Google Scholar
PubMed
Search for other papers by Ricardo S Gomez in
Google Scholar
PubMed
Search for other papers by Marina G Diniz in
Google Scholar
PubMed
Search for other papers by Vanessa F Bernardes in
Google Scholar
PubMed
Search for other papers by Flávia F C Soares in
Google Scholar
PubMed
Search for other papers by João Artur R Brito in
Google Scholar
PubMed
Search for other papers by Sophie Liu in
Google Scholar
PubMed
Search for other papers by Hélder Antônio R Pontes in
Google Scholar
PubMed
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
Search for other papers by Carolina C Gomes in
Google Scholar
PubMed
well as facial deformity ( Praetorius 2009 ). Therefore, elucidation of the molecular pathogenesis of these lesions may be useful in designing targeted therapies to be used in large, destructive, aggressive, or recurrent cases. Mixed odontogenic tumors
Search for other papers by Catalina Simion in
Google Scholar
PubMed
Search for other papers by Maria Elvira Cedano-Prieto in
Google Scholar
PubMed
Search for other papers by Colleen Sweeney in
Google Scholar
PubMed
correlate with EGFR expression ( Nagata et al . 2014 ). LRIG1 down-regulation may have potential as a marker of malignancy in a tumor type which completely lacks molecular markers. Much less is known regarding LRIG2 and LRIG3 expression in cancer and
Search for other papers by Claudia Lanari in
Google Scholar
PubMed
Search for other papers by Victoria Wargon in
Google Scholar
PubMed
Search for other papers by Paola Rojas in
Google Scholar
PubMed
Search for other papers by Alfredo A Molinolo in
Google Scholar
PubMed
express estrogen receptor alpha (ERα) and respond to antiestrogen therapies. These carcinomas may also express progesterone receptors (PRs), which are a reliable marker of functional ERs ( Kastner et al . 1990 , Petz & Nardulli 2000 ). In this paper, we
Search for other papers by Y Capodanno in
Google Scholar
PubMed
Search for other papers by F O Buishand in
Google Scholar
PubMed
Search for other papers by L Y Pang in
Google Scholar
PubMed
Search for other papers by J Kirpensteijn in
Google Scholar
PubMed
Search for other papers by J A Mol in
Google Scholar
PubMed
Search for other papers by D J Argyle in
Google Scholar
PubMed
-express both endocrine and exocrine markers ( Ordonez 2001 ). Furthermore, recent studies have identified CD90 as a potential marker for CSCs in a human INS cell line ( Buishand et al . 2016 ). However, there are no consensus markers available to identify INS
Search for other papers by Rossella Libè in
Google Scholar
PubMed
Search for other papers by Amato Fratticci in
Google Scholar
PubMed
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
markers have demonstrated a high percentage of loss of heterozygosity (LOH) or allelic imbalance at 11q13 (≥90%), 17p13 (≥85%), and 2p16 (92%) in ACC ( Kjellman et al. 1999 , Gicquel et al. 2001 ). The genes involved in these molecular
Search for other papers by Y M H Jonkers in
Google Scholar
PubMed
Search for other papers by S M H Claessen in
Google Scholar
PubMed
Search for other papers by A Perren in
Google Scholar
PubMed
Search for other papers by S Schmid in
Google Scholar
PubMed
Search for other papers by P Komminoth in
Google Scholar
PubMed
Search for other papers by A A Verhofstad in
Google Scholar
PubMed
Search for other papers by L J Hofland in
Google Scholar
PubMed
Search for other papers by R R de Krijger in
Google Scholar
PubMed
Search for other papers by P J Slootweg in
Google Scholar
PubMed
Search for other papers by F C S Ramaekers in
Google Scholar
PubMed
Search for other papers by E-J M Speel in
Google Scholar
PubMed
). When only a primary lesion is identified, however, no reliable markers for malignancy are available. At best a tumor diameter ≥2 cm, an increased mitotic index and necrosis seem to indicate an increased risk for malignancy ( Hochwald et al. 2002 ). It
Hormonal Biology Laboratory, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Fidéline Bonnet-Serrano in
Google Scholar
PubMed
Department of Endocrinology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
biomarker remained a significant prognostic factor for DFS and OS in multivariate analysis including ENSAT stage and Ki67. This biomarker seems particularly attractive, most of the previous reported molecular markers being only investigated in univariate
Search for other papers by Shyh-Han Tan in
Google Scholar
PubMed
Search for other papers by Marja T Nevalainen in
Google Scholar
PubMed
with the circulating PRL levels yielded controversial results. Potential molecular mechanisms and factors, in addition to pituitary and autocrine GH and PRL underlying the constitutive activation of STAT5A/B signaling pathway in prostate and breast
